SCYNEXIS (SCYX) Stock Forecast, Price & News

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

Is SCYNEXIS a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS or view top-rated stocks.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for SCYNEXIS.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.56. During the same quarter last year, the firm earned ($0.23) earnings per share.
View SCYNEXIS's earnings history.

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

SCYNEXIS shares reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

3 Wall Street analysts have issued 1-year price targets for SCYNEXIS's shares. Their forecasts range from $8.00 to $35.00. On average, they expect SCYNEXIS's stock price to reach $21.50 in the next year. This suggests a possible upside of 914.2% from the stock's current price.
View analysts' price targets for SCYNEXIS or view top-rated stocks among Wall Street analysts.

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:

• Dr. Marco Taglietti M.D., CEO, Pres & Director (Age 62, Pay $991.27k)
• Mr. David Gonzalez Angulo, Chief Medical Officer (Age 57, Pay $709.66k)
• Mr. Lawrence R. Hoffman CPA, Esq., Interim CFO & Principal Accounting Officer (Age 67)
• Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 44)
• Debbie Etchison, Exec. Director of Communications
• Dr. Rajeshwar Motheram, Sr. VP of Pharmaceutical Devel. & Supply Chain
• Ms. Christine R. Coyne M.B.A., Chief Commercial Officer

Who are some of SCYNEXIS's key competitors?

Some companies that are related to SCYNEXIS include LianBio (LIAN), AC Immune (ACIU), Ocular Therapeutix (OCUL), Precigen (PGEN), VBI Vaccines (VBIV), Provention Bio (PRVB), Lexicon Pharmaceuticals (LXRX), ESSA Pharma (EPIX), MacroGenics (MGNX), Gracell Biotechnologies (GRCL), Alpine Immune Sciences (ALPN), Immutep (IMMP), Verastem (VSTM), Nature's Sunshine Products (NATR) and VistaGen Therapeutics (VTGN).
View all of SCYX's competitors.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (7.73%), Worth Venture Partners LLC (1.72%), Decheng Capital Management III Cayman LLC (1.92%), D.A. Davidson & CO. (1.02%), State Street Corp (0.27%) and Chicago Partners Investment Group LLC (0.15%). Company insiders that own SCYNEXIS stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends for SCYNEXIS.

Which institutional investors are selling SCYNEXIS stock?

SCYX stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC.
View insider buying and selling activity for SCYNEXIS or view top insider-selling stocks.

Which institutional investors are buying SCYNEXIS stock?

SCYX stock was bought by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, AIGH Capital Management LLC, Worth Venture Partners LLC, Chicago Partners Investment Group LLC, State Street Corp, Citigroup Inc., D.A. Davidson & CO., and Group One Trading L.P.. Company insiders that have bought SCYNEXIS stock in the last two years include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, and Scott Sukenick.
View insider buying and selling activity for SCYNEXIS or or view top insider-buying stocks.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $2.12.

How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of $69.07 million and generates $13.16 million in revenue each year. The company earns $-32.87 million in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does SCYNEXIS have?

SCYNEXIS employs 38 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at (201) 884-5485, via email at [email protected], or via fax at 201-884-5490.